An arrhythmia is a problem with the speed or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. A heartbeat that is too fast is called tachycardia. A heartbeat that is too slow is called bradycardia. Most arrhythmias are harmless, but some can be serious or even life threatening. When the heart rate is too slow, too fast, or irregular, the heart may not be able to pump enough blood to the body. Lack of blood flow can damage the brain, heart, and other organs.
Use of TYRX, Inc.'s AIGISRx- Antibacterial Envelope reduced major infection rates by more than 90% in patients undergoing Cardiovascular Implantable Electronic Device replacement procedures compared to similar high-risk cohorts, according to the CITADEL & CENTURION clinical study results presented on Saturday at the Late Breaking Clinical Trials session at Heart Rhythm 2013, the Heart Rhythm Society's 34th Annual Scientific Sessions.
A new Canadian study shows that operating without interrupting warfarin treatment at the time of cardiac device surgery is safe and markedly reduces the incidence of clinically significant hematomas compared to the current standard of care.
Aviir Inc., a biotechnology company dedicated to the prevention of cardiovascular disease through innovative laboratory tests, announced that it will be extending its offered services with comprehensive inherited cardiovascular disease genetic test menu.
Colorado Governor John W. Hickenlooper has proclaimed May to be Cardiac Arrhythmia Awareness Month (#RhythmAwareness), calling attention to the need for greater public awareness throughout the State about two serious heart rhythm disorders, atrial fibrillation (also known as AF or AFib) and sudden cardiac arrest (also known as SCA).
Inherited ventricular arrhythmias are an important cause of morbidity and sudden cardiac death in children who have structurally normal hearts. Despite conventional medical therapy, some of these children remain symptomatic with recurrent life-threatening arrhythmias, syncope, or frequent discharges from implantable cardioverter defibrillators.
BIOTRONIK, a leading manufacturer of cardiovascular medical technology, announced that the Food and Drug Administration granted approval for its Ilesto 7 implantable cardioverter-defibrillator/cardiac resynchronization therapy defibrillator series.
A new stress test protocol that investigates reducing the use of perfusion imaging in low risk patients undergoing SPECT myocardial perfusion imaging for possible angina symptoms was found to be diagnostically safe, revealed a US retrospective analysis.
The U.S. Food and Drug Administration's warning that high doses of the antidepressant citalopram can cause potentially serious abnormal heart rhythms might be doing more harm than good.
Martindale Pharma, a leader in the manufacture and supply of specialty pharmaceuticals, is pleased to announce the UK launch of Prenoxad Injection, the world's first licensed emergency treatment for acute opioid related overdose for use at home or other non-medical settings.
Unrecognized atrial fibrillation could be a cause of some wake-up strokes, say researchers who found an increased prevalence of the arrhythmia in patients who had stroke symptoms on waking.
Bausch + Lomb, the global eye health company and Paragon BioTeck, Inc. today announced that the companies have entered into a license agreement for Bausch + Lomb to commercialize and distribute Paragon's phenylephrine in the United States on an exclusive basis beginning this month.
A study published today in the European Heart Journal found no evidence that digoxin increases mortality in patients with atrial fibrillation, the opposite of results just published by another group in the same journal analyzing the same data.
Doctors at UCSF Medical Center implanted a new cardiac defibrillator that uses a single-lead to sense vital changes in the heart rhythm on March 14, 2013, becoming one of the first heart centers in Northern California to perform this procedure.
Computational models of the human heart can be very useful in studying not just the basic mechanisms of heart function, but also to analyze the heart in a diseased state, and come up with methods for diagnosis and therapy.
Risk prediction tools that estimate future risk of heart disease and stroke may be more useful predictors of future decline in cognitive abilities, or memory and thinking, than a dementia risk score, according to a new study published in the April 2, 2013, print issue of Neurology®, the medical journal of the American Academy of Neurology.
New research from UC Davis published in the Proceedings of the National Academy of Sciences shows that blocking an enzyme that promotes inflammation can prevent the tissue damage following a heart attack that often leads to heart failure.
A study of nearly 4000 pairs of mothers and their children in the Children of the 90s study at the University of Bristol has shown that maternal vitamin D levels during pregnancy are not associated with the child’s bone health in later life. The research, published Online First in The Lancet, is the largest ever observational study of the effects of mothers’ vitamin D levels in pregnancy on their children’s bone health, and suggests that UK health guidelines may be overstating the importance of vitamin D supplementation in pregnancy.
For the first time, a UCLA team has used a technique normally employed in treating brain aneurysms to treat severe, life-threatening irregular heart rhythms in two patients.
Detection of midwall fibrosis (the presence of scar tissue in the middle of the heart muscle wall) via magnetic resonance imaging among patients with nonischemic dilated cardiomyopathy (a condition affecting the heart muscle) was associated with an increased likelihood of death.
In a new phase III trial mirabegron, a β3-adrenoceptor agonist, given once daily for 12 weeks, reduced the frequency of incontinence episodes and number of daily urinations, and improved urgency and nocturia in adults with overactive bladder compared to those in a placebo group.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.